Treatment strategies for amyloid A amyloidosis

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 12, 2008, Pages 2117-2128

  Pettersson, T ^a   Konttinen, Y T ^a,b,c   Maury, C Peter J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b ORTON ORTHOPAEDIC HOSPITAL   (Finland)

^c COXA Hospital for Joint Replacement ^*  (Finland)

Author keywords

Amyloid A amyloidosis; Anticytokine agents; Cytokines; Eprodisate; Fibril dissolution; Glycosaminoglycans; Serum amyloid A; Serum amyloid P component

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID A PROTEIN; AMYLOID P COMPONENT; ATLIZUMAB; C REACTIVE PROTEIN; COLCHICINE; CYTOTOXIC AGENT; EPRODISATE; ETANERCEPT; GLYCOSAMINOGLYCAN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR ANTIBODY; PLACEBO; PYRROLIDINE DERIVATIVE; RECEPTOR ANTIBODY; RO 63 8695; SULFONIC ACID DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

AMYLOID A AMYLOIDOSIS; AMYLOIDOSIS; ANTIINFLAMMATORY ACTIVITY; CINCA SYNDROME; CLINICAL TRIAL; CROHN DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENTERITIS; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FAMILIAL MEDITERRANEAN FEVER; GENE MUTATION; GENETIC PREDISPOSITION; GLOMERULONEPHRITIS; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIGAND BINDING; MUCKLE WELLS SYNDROME; NEPHROTIC SYNDROME; PATHOGENESIS; PATIENT COMPLIANCE; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEINURIA; RENAL REPLACEMENT THERAPY; REVIEW; RHEUMATIC DISEASE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME;

AMYLOIDOSIS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; CYTOKINES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SERUM AMYLOID A PROTEIN; SERUM AMYLOID P-COMPONENT;

EID: 50949126094     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.12.2117     Document Type: Review

References (109)

1. Pepys MB. Amyloidosis. Ann Rev Med 2006;57:223-41
2. Husby G, Marhaug G, Dowton B, et al. Serum amyloid A (SAA): biochemistry, genetics and the pathogenesis of AA amyloidosis. Amyloid 1994;1:119-37
3. Merlini G, Westermark P. The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies. J Int Med 2004;255:159-78
4. Ajiro J, Narita I, Sato F, et al. SAA1 gene polymorphisms and the risk of AA amyloidosis in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2006;16:294-9
5. Maury CPJ, Aittoniemi J, Tiitinen S, et al. Variant mannose-binding lectin 2 genotype is a risk factor for reactive systemic amyloidosis in rheumatoid arthritis. J Int Med 2007;262:466-9
6. Hasegawa H, Nishi SI, Ito S, et al. High prevalence of serum apolipoprotein E4 isoprotein in rheumatoid arthritis patients with amyloidosis. Arthritis Rheum 1996;39:1728-32
7. Maury CPJ, Liljeström M, Tiitinen S, et al. Apolipoprotein E phenotypes in rheumatoid arthritis with or without amyloidosis. Amyloid 2001;8:270-3
8. deBeer FC, Mallya RK, Fagan EA, et al. Serum amyloid A protein (SAA) concentration in inflammatory disease and its relationship to the incidence of reactive systemic amyloidosis. Lancet 1982;2:231-4
9. Myllykangas-Luosujärvi R, Aho K, Kautiainen H, et al. Amyloidosis in a nationwide series of 1666 subjects with rheumatoid arthritis who died during 1989 in Finland. Rheumatology 1999;38:499-503
10. Laiho K, Tiitinen S, Kaarela K, et al. Secondary amyloidosis has decreased in patients with inflammatory joint disease in Finland. Clin Rheumatol 1999;18:122-3
11. Hazenberg BPC, Van Rijswijk MH. Where has secondary amyloidosis gone? Ann Rheum Dis 2000;59:577-9
12. Tunca M, Akar S, Onen F, et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine 2005;84:1-11
13. Touitou I, Sarkisian T, Medlej-Hashim M, et al. Country as the primary risk factor for amyloidosis in familial Mediterranean fever. Arthritis Rheum 2007;56:1706-12
14. Greenstein AJ, Sachar DB, Panday AK, et al. Amyloidosis and inflammatory bowel disease. A 50 year experience with 25 patients. Medicine 1992;71:261-70
15. Lähdevirta J, Maury CPJ, Teppo AM, et al. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med 1988;85:289-91
16. Maury CPJ, Juvonen ER, Lähdevirta J, et al. Mechanism of anaemia and cachexia of chronic disease: evidence for a role of interleukin 1β and tumour necrosis factor-α. Eur J Int Med 1991;2:159-64
17. Roubenoff R. Physical activity, inflammation, and muscle loss. Nutr Rev 2007;65:S208-12
18. Maury CPJ, Andersson LC, Teppo AM, et al. Mechanism of anaemia in rheumatoid arthritis: demonstmtion of raised interleukin 1β concentrations in anemic patients and of interleukin 1 mediated suppression of normal erythropoiesis and proliferation of human erythroleukemia (HEL) cells in vitro. Ann Rheum Dis 1988;47:972-8
19. Maury CPJ, Liljeström M, Laiho K, et al. Tumor necrosis factor-α, its soluble receptor 1 and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis. Indications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis. Arthritis Rheum 2003; 48:3068-76
20. Maury CPJ, Liljeström M, Laiho K, et al. Anaemia of chronic disease in AA amyloidosis is associated with allele 2 of the interleukin-1β-511 promoter gene and raised levels of interleukin-1β and interleukin-18. J Int Med 2004;256:145-52
21. Maury CPJ, Tiitinen S, Laiho K, et al. Raised circulating interleukin-18 levels in reactive AA-amyloidosis. Amyloid 2002;9:141-4
22. Migita Y, Yamasaki S, Shibatomi K, et al. Impaired degradation of serum amyloid A (SAA) protein by cytokine-stimulated monocytes. Clin Exp Immunol 2001;123:408-11
23. Falck HM, Maury CPJ, Teppo AM, et al. Correlation of persistently high serum amyloid A protein and C-reactive protein concentrations with rapid progression of secondary amyloidosis. BMJ 1983;286:1391-3
24. Lachmann HJ, Goodman HJB, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356:2361-71
25. Brennan FM, Chantry D, Jackson A, et al. Inhibitory effects of TNFα antibodies on synovial cell interleukin-I production in rheumatoid arthritis. Lancet 1989;ii:244-7
26. Souza DG, Guabiraba R, Pinho V, et al. IL-1-driven endogenous IL-10 production protects against the systemic and local acute inflammatory response following intestinal reperfusion injury. J Immunol 2003;170:4759-66
27. Netea MG, Kullberg BJ, Boerman OC, et al. Soluble murine IL-1 receptor type I induces release of constitutive IL-1α. J Immunol 1999; 162:4876-81
28. Oldenburg HS, Rogy MA, Lazarus DD, et al. Cachexia and the acute-phase protein response in inflammation are regulated by interleukin-6. Eur J Immunol 1993;23:1889-94
29. Malfait AM, Verbruggen G, Veys EM, et al. Comparative and combined effects of interleukin 6, interleukin 1 beta, and tumor necrosis factor alpha on proteoglycan metabolism of human articular chondrocytes cultured in agarose. J Rheumatol 1994;21:314-20
30. Matsuno H, Yudoh K, Katayama R, et al. The role of TNF-alpha in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera. Rheumatology (Oxford) 2002;41:329-37
31. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002;10:417-26
32. Agostini L, Martinon F, Burns K, et al. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004;20:319-25
33. Keller M, Rüegg A, Werner S, et al. Active caspase-1 is a regulator of unconventional protein secretion. Cell 2008;132:818-31
34. Mihara M, Shiina M, Nishimoto N, et al. Anti-interleukin 6 receptor antibody inhibits murine AA-amyloidosis. J Rheumatol 2004;31:1132-8
35. Dinarello CA. IL-18: a TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. Allergy Clin Immunol 1999;103:11-24
36. Tanaka F, Migita K, Kawabe Y, et al. Interleukin-18 induces serum amyloid A (SAA) protein production from rheumatoid synovial fibroblasts. Life Sci 2004;74:1671-9
37. Gracie JA, Forsey RJ, Ling Chan W, et al. A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 1999;104:1393-401
38. Shapiro DL, Spiera H. Regression of the nephrotic syndrome in rheumatoid arthritis and amyloidosis treated with azathioprine: a case report. Arthritis Rheum 1995;38:1851-4
39. Komatsuda A, Morita Y, Ohtani H, et al. Remission of the nephrotic syndrome in a patient with renal amyloidosis due to rheumatoid arthritis treated with prednisolone and methotrexate. Am J Kidney Dis 1998;32:E7
40. Ahlmen M, Ahlmen J, Svalander C, Bucht H. Cytotoxic drug treatment of reactive amyloidosis in rheumatoid arthritis with special reference to renal insufficiency. Clin Rheumatol 1987;6:27-38
41. Berglund Y, Keller C, Thysell H. Alkylating cytostatic treatment in renal amyloidosis secondary to rheumatoid disease. Ann Rheum Dis 1987;46:757-62
42. Savolainen HA. Chlorambucil in severe juvenile chronic arthritis: longterm follow-up with special reference to amyloidosis. J Rheumatol 1999;26:898-903
43. Elkayam O, Hawkins PN, Lachmann H, et al. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum 2002;46:2571-3
44. Gottenberg JE, Merle-Vincent F, Bentaberry F, et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a follow-up report of tolerability and efficacy. Arthritis Rheum 2003;48:2019-24
45. Nakamura T, Higashi S, Tomoda K, et al. Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis. Clin Exp Rheumatol 2007;25:518-22
46. Perry ME, Stirling A, Hunter JA. Effect of etanercept on serum amyloid A protein (SAA) levels in patients with AA amyloidosis complicating inflammatory arthritis. Clin Rheumatol 2008; [Epub ahead of print]
47. Maini RN, Taylor OPC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-29
48. Okuda Y, Takasugi K. Successful use of humanized anti-interleukin-6 receptor antobody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum 2006;54:2997-3000
49. Gillmore JD, Lovat LB, Persey MR, et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001;358:24-9
50. Yan SD, Zhu H, Zhu A, et al. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 2000;6:643-51
51. Ganapathi MK, May LT, Scultz D, et al. Role of interleukin-6 in regulating synthesis of C-reactive protein and serum amyloid A in human hepatoma cell lines. Biochem Biophys Res Commun 1988;157:271-7
52. Grehan S, Uhlar CM, Sim RB, et al. Expression of biologically active recombinant mouse IL-1 receptor antagonist and its use in vivo to modulate aspects of the acute phase response. J Immunol 1997;159:369-78
53. Rokita H, Loose LD, Bartle LP, Sipe JD. Synergism of interleukin 1 and interleukin 6 induces serum amyloid A production while depressing fibrinogen: a quantitative analysis. J Rheumatol 1994;21:400-5
54. Leslie KS, Lachmann HJ, Bruning E, et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol 2006;142:1591-7
55. Thornton BD, Hoffman HM, Bhat A, Don BR. Successful treatment of renal amyloidosis due to familial cold autoinflammatory syndrome using an interleuldn 1 receptor antagonist. Am J Kidney Dis 2007;49:477-81
56. Stojanoy S, Kastner DL. Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol 2005;17:586-99
57. Brydges S, Kastner DL. The systemic autoinflammatory diseases: inborn errors of the innate immune system. CTMI 2006;305:127-60
58. Padeh S, Berkun Y. Auto-inflammatory fever syndromes. Rheum Dis Clin North Am 2007;33:585-623
59. Stankovic K, Grateau G. Autoinflammatory syndromes: diagnosis and treatment. J Bone Spine 2007;74:544-50
60. Grateau G. Musculoskeletal disorders in secondary amyloidosis and hereditary fevers. Best Pract Res Clin Rheumatol 2003;17:929-44
61. Grateau G, Jeru I, Rouaghe S, et al. Amyloidosis and autoinflammatory syndromes. Curr Drug Targets Inflamm Allergy 2005;4:57-65
62. Van der Hilst JCH, Simon A, Drenth JPH. Hereditary periodic fever and reactive amyloidosis. Clin Exp Med 2005;5:87-98
63. Zemer D, Pras M, Sohar F, et al. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 1986;314:1001-5
64. Calganeri M, Apras S, Ozbalkan Z, et al. The efficacy of continuous interferon alfa administration as an adjunctive agent to colchicine resistant familial Mediterranean fever patients. Clin Exp Rheumatol 2004;22:S41-4
65. Belkhir R, Moulonguet-Doleris L, Haculla F, et al. Treatment of familial Mediterranean fever with anakinra. Ann Intern Med 2007;146:825-6
66. Hull KM, Drewe E, Aksentijevich I, et al. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 2002;81:349-68
67. Drewe E, McDermott EM, Powell PT, et al. Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and a case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor-associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients. Rheumatology (Oxford) 2003;42:235-9
68. Drewe E, McDermott EM, Powell RJ. Treatment of the nephrotic syndrome with etanercept in patients with the tumor necrosis factor receptor-associated periodic syndrome. N Engl J Med 2000;343:1044-5
69. Simon A, Bodar EJ, van der Hilst JC, et al. Beneficial response to interleukin 1 receptor antagonist in TRAPS. Am J Med 2004;117:208-10
70. Hawkins PN, Lachmann HJ, Aganna E, et al. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004;50:607-12
71. Hoffman HM, Rosengren S, Boyle DL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004;364:1779-85
72. Thornton BD, Hoffman HM, Bhat A, Don BR. Successful treatment of renal amyloidosis due to familial cold autoinflammatory syndrome using an interleukin 1 receptor antagonist. Am J Kidney Dis 2007;49:477-81
73. Aganna E, Hawkins PN, Ozen S, et al. Allelic variants in genes associated with hereditary periodic fever syndrome as susceptibility factors for reactive systemic AA amyloidosis. Genes Immun 2004;5:289-93
74. Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. N Engl J Med 2006;355:581-92
75. Obici L, Manno C, Muda AO, et al. First report of systemic reactive (AA) amyloidosis in a patient with the hyperimmunoglobulinemia D with periodic fever syndrome. Arthritis Rheum 2004;50:2966-9
76. Lachmann HJ, Goodman HJB, Andrews PA, et al. AA amyloidosis complicating hyperimmunoglobulinemia D with periodic fever syndrome. Arthritis Rheum 2006;54:2010-4
77. Siewert R, Ferber J, Horstmann RD, et al. Hereditary periodic fever with systemic amyloidosis: is hyper-IgD syndrome really a benign disease. Am J Kidney Dis 2006;48:E41-5
78. Takada K, Aksentijevich I, Mahadevan V, et al. Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 2003;48:2645-51
79. Cailliez M, Garaix F, Rousset-Rouviere C, et al. Anakinra is safe and effective in controlling hyperimmunoglobulinemia D syndrome-associated febrile crisis. J Inherit Metab Dis 2006;29:763
80. Simon A, Drewe E, van der Meer JW, et al. Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther 2004;75:476-83
81. Van der Hilst JCH, Kluve-Beckerman B, Bodar EJ, et al. Lovastatin inhibits formation of AA amyloid. J Leukocyt Biol 2008;83:1295-9
82. Mullin GE, Lazenby AJ, Harris ML, et al. Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ulcerative colitis. Gastroenetrology 1992;102:1620-7
83. Fuss IJ, Neurath M, Boivirant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease: Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996;157:261-70
84. Murch SH, Lamkin VA, Savage MO, et al. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991;32:913-7
85. Gonvers JJ, Julierat P, Mottet C, et al. Maintenance of medically induced remission of Crohn's disease. Digestion 2007;76:116-29
86. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369:1641-5
87. Iizuka M, Konno S, Horie Y, et al. Infliximab as a treatment for systemic amyloidosis associated with Crohn's disease. Gut 2006;55:744-5
88. Bosca MM, Perez-Baylach CM, Solis MA, et al. Secondary amyloidosis in Crohn's disease. Treatment with tumour necrosis factor inhibitor. Gut 2006;55:284-5
89. Fernandez-Nebro A, Urena I, Irigoyen MV, et al. Anti-TNF-α for treatment of amyloidosis associated with Crohn's disease. Gut 2006;55:1666-7
90. Amemori S, Iwakiri R, Endo H, et al. Oral dimethyl sulfoxide for systemic AA amyloidosis complication in chronic inflammatory disease: a retrospective patient chart review. J Gastroenterol 2006;41:444-9
91. Iwakiri R, Sakemi T, Fujimoto K. Dimethylsulfoxide for renal dysfunction caused by systemic amyloidosis complicating Crohn's disease. Gastroenterology 1999;117:1031-2
92. Hazenberg BPC, van Rijswijk MH. Clinical and therapeutic aspects of AA amyloidosis. Baillieres Clin Rheumatol 1994;8:661-90
93. Knutar O, Pertersson T, Törnroth T, Maury CPJ. AA amyloidosis without definable underlying disease. In: Bely M, Apathy A, editors, Amyloid and amyloidosis. Proceedings of the IX International Symposium on Amyloidosis. Budapest, Hungary; 2001. p. 168-70
94. Bergesio F, Ciciani AM, Manganaro M. Renal involvement in systemic amyloidosis. Nephrol Dial Transplant 2008;23:941-51
95. Immonen K, Finne P, Hakala M, et al. No improvement in survival of patients with amyloidosis associated with inflammatory rheumatic diseases. Data from the Finnish national registry for kidney diseases. J Rheumatol 2008; [Epub ahead of print]
96. Heering P, Hetzel R, Grabensee B, et al. Renal transplantation in secondary systemic amyloidosis. Clin Transplant 1998;12:159-64
97. Keven Y, Sengui S, Kutlay S, et al. Long-term outcome of renal transplantation in patients with familial Mediterranean fever amyloidosis: a single-center experience. Transplant Proc 2004;36:2632-4
98. Pepys MB, Herbert J, Hutchinson W, et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002;417:254-9
99. Dember LM, Hawkins PN, Hazenberg BPC, et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 2007;356:2349-60
100. McInnes IB, Liew FY. Cytokine networks - towards new therapies for rheumatoid arthritis. Nat Clin Pract Rheumatol 2005;1:31-9
101. Rochet JC. Novel therapeutic strategies for the treatment of protein-misfolding diseases. Expert Rev Mol Med 2007;28:1-34
102. Sacchettini JC, Kelly JW. Therapeutic strategies for human amyloid diseases. Nat Rev Drug Res 2002;1:267-75
103. O'Nuallain B, Wetzel R. Conformational Abs recognizing a generic amyloid fibril epitope. Proc Natl Acad Sci USA 2002;99:1485-90
104. McGavern DB. Immunotherapeutic relief from persistent infections and amyloid disorders. Neurology 2006;66(Suppl 1):S59-64
105. Wisniewski T, Frangione B. Immunological and anti-chaperone therapeutic approaches for Alzheimer disease. Brain Pathol 2005;15:72-7
106. Li J-P, Galvis MLE, Gong F, et al. in vivo fragmentation of heparan sulfate by heparanase overespression renders mice resistant to amyloid protein A amyloidosis. Proc Natl Acad Sci USA 2005;102:6473-7
107. Lidar M, Livneh A. Familial Mediterranean fever: clinical, molecular and management advancements. Neth J Med 2007;6:318-24
108. Kobak S, Oksel F, Kabasakai Y, et al. Ankylosing spondylitis-related secondary amyloidosis responded to etanercept: a report of three patients. Clin Rheumatol 2007;26:21291-4
109. Nishimoto N, Sasai M, Shima Y, et al. Improvement of Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000;85:56-61